Rising Interleukin-8 Levels in Blood May Signal Gastric Cancer Months Before Diagnosis

Gastric cancer continues to rank among the deadliest malignancies on the planet, largely because it tends to announce itself late. By the time symptoms drive patients to the clinic, the disease has often advanced beyond the point where curative treatment is possible. A new prospective study from Egypt now suggests that a simple, serially measured blood protein could flag the transition from harmless-looking stomach inflammation to full-blown cancer months before any tumor is clinically detected, offering a potential early-warning system for one of medicine’s most silent killers.

The research, published in the journal Gut Pathogens, tracked patients with Helicobacter pylori–associated precancerous stomach lesions over two years, repeatedly measuring levels of interleukin-8, a pro-inflammatory chemokine long implicated in the biology of gastric carcinogenesis. The findings indicate that the trajectory of IL-8 over time, rather than a single snapshot, carries meaningful predictive information about which patients will progress toward malignancy. In an era when precision oncology increasingly depends on molecular signals rather than gross symptoms, the study adds a potentially valuable piece to the biomarker puzzle.

The scientific rationale behind the work rests on the well-characterized inflammatory cascade that H. pylori initiates in the gastric mucosa. This bacterium colonizes the stomach lining of roughly half the global population, and while most carriers never fall ill, a subset develops a stepwise sequence of pathology: chronic gastritis, atrophic gastritis, intestinal metaplasia, and eventually adenocarcinoma. Interleukin-8 sits at a critical junction in this process. The chemokine is secreted by gastric epithelial cells and macrophages in response to H. pylori infection and acts as a potent recruiter of neutrophils, sustaining the chronic inflammatory milieu that drives DNA damage, cell turnover, and, ultimately, neoplastic transformation. Tumor cells themselves also produce IL-8, where it promotes angiogenesis, proliferation, and metastatic behavior, which makes the molecule interesting both as a consequence of inflammation and as a possible engine of cancer progression.

To test whether circulating IL-8 could serve as a practical surveillance tool, the investigators designed a multicenter, prospective longitudinal cohort study spanning five Egyptian centers. They enrolled 200 participants distributed across five groups: 50 patients with atrophic gastritis, 50 with intestinal metaplasia, 25 with H. pylori–positive gastric cancer, 25 with H. pylori–negative gastric cancer, and 50 healthy controls. Every participant underwent baseline clinical assessment, laboratory evaluation including the established tumor markers CEA and CA19-9, H. pylori testing by stool antigen assay and urea breath test performed according to the Maastricht VI consensus guidelines, and endoscopy with histopathology interpreted under the Updated Sydney System. Critically, the 100 patients with precancerous lesions were then followed for 24 months, with serum IL-8 measured at 0, 6, 12, 18, and 24 months and a repeat endoscopy performed at the end of the observation period.

The baseline cross-sectional results alone were striking. Mean serum IL-8 climbed in a stepwise fashion across the disease spectrum: healthy controls averaged 9.7 picograms per milliliter, patients with atrophic gastritis 42.1, those with intestinal metaplasia 64.8, and those with established gastric cancer 107.4, a gradient that was highly statistically significant. Notably, IL-8 elevation in cancer patients appeared independent of H. pylori status, with comparable levels in H. pylori–positive and H. pylori–negative tumors. The authors caution, however, that these stage-stratified subgroup comparisons involved small numbers and should be regarded as exploratory. Nevertheless, the pattern is biologically coherent: as the gastric mucosa marches through the precancerous cascade, the inflammatory chemokine burden in the circulation appears to rise in parallel, reflecting the escalating molecular chaos within the stomach wall.

The longitudinal data proved even more informative. Of the 100 patients with precancerous lesions, 94 completed the full follow-up, and 9 of them progressed to gastric cancer during the study, 7 from intestinal metaplasia and 2 from atrophic gastritis. Using a cutoff of 52.3 picograms per milliliter at baseline, elevated IL-8 was associated with subsequent progression, achieving an area under the receiver operating characteristic curve of 0.84, with sensitivity of 88.9 percent, specificity of 78.0 percent, and a negative predictive value of 98.5 percent. That last figure deserves emphasis: a normal IL-8 level at a given visit was an extraordinarily reassuring finding, correctly identifying nearly 99 percent of patients who did not go on to develop cancer within the follow-up window. The established markers fared far worse, with CEA yielding an AUC of 0.62 and CA19-9 an AUC of 0.58, both barely better than chance in this setting.

Because the true power of a surveillance biomarker lies in its performance over time, the researchers applied time-dependent ROC analysis using a cumulative and dynamic approach. The discriminatory capacity of serial IL-8 strengthened as follow-up accumulated: the time-dependent AUC rose to 0.91 at 12 months and reached 0.94 at 18 months. In other words, the longer the team watched a patient’s IL-8 curve, the more accurately they could distinguish the individuals on a path to malignancy from those whose lesions would remain stable. This dynamic behavior is precisely what one hopes for from a monitoring strategy, since clinical decisions about escalating endoscopic surveillance depend on recognizing change rather than on static risk estimates made once at enrollment.

To capture that change formally, the team employed group-based trajectory modeling, executed while blinded to outcome status, which stratified the 100 patients into three distinct patterns of IL-8 behavior: a Stable-Low group of 42 patients, a Moderate-Rising group of 49, and a High-Accelerating group of 9. Every single patient in the High-Accelerating group progressed to gastric cancer, and the acceleration point in their IL-8 curves preceded the clinical diagnosis by a median of six months, with a range of three to twelve months. The researchers are appropriately measured about this observation, describing it as exploratory and hypothesis-generating and stressing that external validation is required before any causal or firm clinical interpretation. Still, the notion that a molecular inflection point in the bloodstream can herald cancer’s arrival by half a year is a tantalizing clue for early detection.

The statistical analysis also grappled with a challenge familiar to anyone studying rare events: only 9 progression events occurred, which limits the power of conventional regression. The investigators therefore used multivariable logistic regression with Firth penalization, a technique designed to reduce bias in small-sample, low-event settings. In that model, baseline IL-8 emerged as an independent predictor of progression, with an adjusted odds ratio of 2.31 for every 10-picogram-per-milliliter increase (95 percent confidence interval 1.48 to 3.61), and the presence of intestinal metaplasia carried an adjusted odds ratio of 4.22 (95 percent confidence interval 1.31 to 13.61). The study’s conclusions additionally report an adjusted hazard ratio of 6.94 for a baseline IL-8 above 52.3 picograms per milliliter, reinforcing the same message: the chemokine’s concentration and the histological stage together define a high-risk profile that standard markers miss.

What would it take to translate these numbers into clinical practice? First, the authors and independent observers alike will want confirmation in larger, geographically diverse cohorts, since the event count here was small and Egypt’s specific epidemiology of gastric cancer may not generalize everywhere. Second, the operational logistics matter: the required IL-8 sampling schedule, assay standardization across laboratories, and cost-effectiveness relative to simply intensifying endoscopic surveillance all remain open questions. Third, a biomarker with 88.9 percent sensitivity and 78.0 percent specificity would likely function best as a triage tool, selecting which patients with atrophic gastritis or intestinal metaplasia need closer endoscopic follow-up rather than replacing endoscopy outright. Yet if the six- to twelve-month lead time observed in the High-Accelerating trajectory is reproduced, the payoff could be substantial, catching tumors at a stage when endoscopic resection can be curative. In a disease that claims hundreds of thousands of lives annually and disproportionately burdens regions where advanced endoscopic infrastructure is scarce, a cheap, repeatable blood test that watches the gastric precancerous cascade in real time would represent a genuinely meaningful advance, and this study offers the most rigorous longitudinal evidence to date that interleukin-8 might be exactly that signal.

Subject of Research: Serum interleukin-8 trajectories as biomarkers of progression from Helicobacter pylori–associated precancerous gastric lesions to gastric cancer

Article Title: Serial serum interleukin-8 trajectories are associated with progression from Helicobacter pylori–associated precancerous lesions to gastric cancer: a prospective longitudinal cohort study

Article References: Semeya, A. A., Abdel Hafez, R. S. A., Elgamal, R., Badr, A., Orabi, M. I., Younis, S. R., Morgan, M. M., Ahmed Hassan, M., Alawy, M. R., & Othman, A. A. A. (2026). Serial serum interleukin-8 trajectories are associated with progression from Helicobacter pylori–associated precancerous lesions to gastric cancer: a prospective longitudinal cohort study. Gut Pathogens. https://doi.org/10.1186/s13099-026-00876-8

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00876-8

Keywords: gastric cancer, interleukin-8, Helicobacter pylori, atrophic gastritis, intestinal metaplasia, biomarker, early detection, prospective cohort study, inflammation, tumor markers, risk stratification, Gut Pathogens